Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Organogenesis HoldingsORGO +2.69%67 EV-to-OCF is 12.71 as of Aug. 10, 2026, which is 22% above its 10-year median of 10.45. GuruFocus rates ORGO with a GF Score™ of 67/100 and a GF Value™ of $3.04 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Organogenesis Holdings ranks worse than 54.08% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Organogenesis Holdings's Enterprise Value is $406.5 Mil.
Organogenesis Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $32.0 Mil. Therefore, Organogenesis Holdings's EV-to-OCF for today is 12.71.
The historical rank and industry rank for Organogenesis Holdings's EV-to-OCF or its related term are showing as below:
ORGO'
s EV-to-OCF Range Over the Past 10 Years
Min: -721.33 Med: 10.45 Max: 468.12
Current: 12.71
During the past 11 years, the highest EV-to-OCF of Organogenesis Holdings was 468.12. The lowest was -721.33. And the median was 10.45.
ORGO's EV-to-OCF is ranked worse than 54.08% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.1
vs ORGO: 12.71
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Organogenesis Holdings's PE Ratio (TTM) for today is calculated as:
Organogenesis Holdings's share price for today is $1.91.
Organogenesis Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.860.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's EV-to-OCF falls into.
Organogenesis Holdings's current Enterprise Value is $406.5 Mil.
Organogenesis Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (ORGO) has a EV-to-OCF of 12.71 as of Aug. 10, 2026. This is 22% above median its historical median of 10.45. According to the industry distribution chart, Organogenesis Holdings ranks #544 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 54.1%.
Is Organogenesis Holdings' EV-to-OCF too high?
Organogenesis Holdings' current EV-to-OCF of 12.71 is 22% above median its 10-year median of 10.45. The Drug Manufacturers industry median EV-to-OCF is 11.10. Organogenesis Holdings' value of 12.71 is 14.5% above this industry median. Based on the distribution chart, Organogenesis Holdings ranks #544 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' EV-to-OCF compare to AKBA and TKNO?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #544 out of 1006 companies for EV-to-OCF. This places Organogenesis Holdings in the lower half of its industry. The industry median EV-to-OCF is 11.10. Organogenesis Holdings' value of 12.71 is 14.5% above this benchmark. While the company's 10-year median is 10.45 vs. the industry median of 11.10, Organogenesis Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.10, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current EV-to-OCF of 12.71 is 14.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current EV-to-OCF is 12.71, which is 22% above median its own 10-year median of 10.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.04, compared to a current price of $1.91 — trading 37.2% below its estimated fair value. The current EV-to-OCF is 12.71, which is 22% above median its 10-year median of 10.45 and 14.5% above the Drug Manufacturers industry median of 11.10. Organogenesis Holdings' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current EV-to-OCF is 12.71 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (ORGO) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of $1.91 is trading 37.2% below its estimated GF Value™ of $3.04.
GuruFocus considers Organogenesis Holdings to be Possible Value Trap.
Key valuation signals for ORGO:
EV-to-OCF: 12.71 (22% above median its 10-year median of 10.45)
GF Value™: $3.04 vs. price of $1.91 (37.2% below fair value)
Industry Position: 14.5% above the Drug Manufacturers median (#544 of 1006)
No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score
Get the complete analysis for ORGO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORGO has been successfully added to your 
